I for one don't mind the lack of attention this stock gets here. It's still under the radar to most retail investors. Meanwhile, the insiders and the hedge funds are loading up. This is only the beginning of a big move up. Just wait until when ganetespib gets publicitiy as potentially one of the most important and versatile new cancer drugs this decade, one that could eventually generate $20 Bil or more easily in annual revenue... then the retail investors will come in full force.
We haven't seen anything yet.